A Pill Instead of a Shot: New Drug Beats Oral Ozempic
Eli Lilly says its once-daily pill orforglipron outperformed oral semaglutide in lowering blood sugar and driving weight loss in a large type 2 diabetes trial.
- Orforglipron, a pill taken once a day, lowered HbA1c by 1.71 to 1.91 percent, compared with 1.47 percent for oral semaglutide.
- In an obesity trial, participants on the highest dose lost about 12.4 percent of their body weight after 72 weeks.
- Unlike Ozempic and Wegovy, the tablet needs no refrigeration, no special timing around meals, and is cheaper to make.
- Eli Lilly has already filed with the U.S. FDA for obesity, and plans to submit for type 2 diabetes later this year.
Is a real anti-obesity drug finally arriving that you do not have to inject into your stomach? It looks that way. Eli Lilly has released results from a large clinical trial in which its once-daily pill orforglipron outperformed the leading oral semaglutide.
The idea is simple. Until now, the strongest drugs in the GLP-1 family, such as Ozempic and Wegovy, came as an injection you give yourself. Now the same class of drug comes as an ordinary tablet, and its first head-to-head fight against an oral rival ended in favor of the newcomer.
How much better is it than oral Ozempic?
The key data come from the ACHIEVE-3 study, published in The Lancet, which put orforglipron and oral semaglutide directly against each other in patients with type 2 diabetes.
After 52 weeks, orforglipron lowered glycated hemoglobin, which doctors call HbA1c and which reflects average blood sugar, by 1.71 to 1.91 percent on average. Oral semaglutide brought HbA1c down by 1.47 percent over the same period. The gap looks small on paper, but in long-term diabetes control every fraction of a percent means fewer complications.
Better sugar control came alongside greater weight loss. That matters because these two effects usually go hand in hand with GLP-1 drugs. If you struggle with both extra weight and high blood sugar, a single pill covers both fronts.
One point is easy to miss: this involved patients with type 2 diabetes, not everyone who wants to slim down. The results do not automatically transfer to healthy people.
Why the pill is a big step
The practical side may be the most interesting part. Injections like Ozempic need refrigeration, so you keep them in the fridge and watch the temperature when you travel. A tablet you simply swallow.
Orforglipron also requires no special timing around meals, which with some oral therapies can be a real nuisance. On top of that, a tablet is cheaper to produce, opening the door to a more affordable therapy for more people.
On weight loss specifically, the full results of the obesity trial, known as ATTAIN-1, were published in The New England Journal of Medicine. There, participants on the highest dose lost an average of about 12.4 percent of their body weight after 72 weeks, roughly 12.4 kilograms for an average patient.
Eli Lilly has already filed its application for the obesity treatment with the U.S. Food and Drug Administration, while it plans to submit for type 2 diabetes later this year. The regulatory road is long, so the drug will not reach pharmacies overnight.
One thing is clear. If the approvals come through, choosing a therapy for blood sugar and weight could become simpler than ever. Would you rather take a pill once a day than reach for a needle every time?
